BRPI0510016A - vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina - Google Patents

vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina

Info

Publication number
BRPI0510016A
BRPI0510016A BRPI0510016-0A BRPI0510016A BRPI0510016A BR PI0510016 A BRPI0510016 A BR PI0510016A BR PI0510016 A BRPI0510016 A BR PI0510016A BR PI0510016 A BRPI0510016 A BR PI0510016A
Authority
BR
Brazil
Prior art keywords
lentiviral vector
protein
vaccine
expression
recombinant lentiviral
Prior art date
Application number
BRPI0510016-0A
Other languages
English (en)
Inventor
Philippe Despres
Pierre Charneau
Frederic Tangy
Marie-Pascale Frenkiel
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BRPI0510016A publication Critical patent/BRPI0510016A/pt
Publication of BRPI0510016B1 publication Critical patent/BRPI0510016B1/pt
Publication of BRPI0510016B8 publication Critical patent/BRPI0510016B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

VETOR LENTIVIRAL RECOMBINANTE PARA EX-PRESSãO DE UMA PROTEìNA DE FLAVIVIRIDAE E APLICAçõES DO MESMO COMO VACINA. A presente invenção refere-se ao uso de um vetor lentiviral recombinante que compreende um fragmento de polinucleotídeo que codifica pelo menos uma proteína de um vírus da família Flaviviridae ou um peptídeo imunogênico de pelo menos 8 aminoácidos dessa proteína, para preparação de uma composição farmacêutica pretendida para a prevenção e/ou o tratamento de uma infecção por Flaviviridae em uma espécie sensível.
BRPI0510016A 2004-05-17 2005-05-16 vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina BRPI0510016B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR0405366 2004-05-17
PCT/IB2005/001753 WO2005111221A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Publications (3)

Publication Number Publication Date
BRPI0510016A true BRPI0510016A (pt) 2007-09-18
BRPI0510016B1 BRPI0510016B1 (pt) 2020-03-10
BRPI0510016B8 BRPI0510016B8 (pt) 2021-05-25

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510016A BRPI0510016B8 (pt) 2004-05-17 2005-05-16 vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina

Country Status (9)

Country Link
US (2) US20090214589A1 (pt)
EP (2) EP1751291B1 (pt)
JP (1) JP2008508863A (pt)
CN (1) CN1981043B (pt)
BR (1) BRPI0510016B8 (pt)
CA (1) CA2564934C (pt)
FR (1) FR2870126B1 (pt)
MX (1) MXPA06013388A (pt)
WO (1) WO2005111221A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1224314T3 (da) 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
CA2721657A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
WO2012021741A2 (en) 2010-08-12 2012-02-16 Clontech Laboratories, Inc. Lateral flow assays for non-diagnostic analytes
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
ES2785503T3 (es) 2015-11-09 2020-10-07 Immune Design Corp Composiciones que comprenden vectores lentivíricos que expresan IL-12 y métodos de uso de los mismos
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
MX2020004833A (es) 2017-11-09 2021-01-08 Pasteur Institut Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334328D1 (de) * 1992-07-16 2010-06-10 Advanced Life Science Inst Inc Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
US5883081A (en) * 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
IL129017A0 (en) 1996-10-17 2000-02-17 Oxford Biomedica Ltd Retroviral vectors
CA2315269A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU4554899A (en) 1998-06-09 1999-12-30 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1224314T3 (da) * 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
EP1092780A1 (en) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Recombiant, replication defective CELO virus and CELO virus DNA
DK1383796T3 (da) 2001-04-04 2009-08-17 Pasteur Institut Neurovirulent stamme af viruset West Nile og anvendelser heraf
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
CN1935258B (zh) 2001-07-27 2013-04-03 惠氏公司 西尼罗河疫苗
AU2003216046B2 (en) 2002-01-10 2008-05-01 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
US20030194392A1 (en) * 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
DE10249594A1 (de) * 2002-10-24 2004-05-13 Jassoy, Christian, Dr. Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
CA2456873A1 (en) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
BRPI0510016B1 (pt) 2020-03-10
CN1981043B (zh) 2010-06-09
US8716013B2 (en) 2014-05-06
EP1751291A1 (en) 2007-02-14
EP2371966B1 (en) 2015-11-25
FR2870126B1 (fr) 2009-07-17
FR2870126A1 (fr) 2005-11-18
CN1981043A (zh) 2007-06-13
US20090214589A1 (en) 2009-08-27
EP2371966A1 (en) 2011-10-05
JP2008508863A (ja) 2008-03-27
MXPA06013388A (es) 2007-06-19
BRPI0510016B8 (pt) 2021-05-25
US20110206710A1 (en) 2011-08-25
EP1751291B1 (en) 2013-07-31
WO2005111221A1 (en) 2005-11-24
CA2564934C (en) 2014-07-08
CA2564934A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BRPI0515516A (pt) composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica
BR112018076437A2 (pt) interferon porcino peguilado e seus métodos de utilização
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
BRPI0708519B8 (pt) vesícula semelhante ao virossoma, composição farmacêutica, uso de pelo menos uma vesícula semelhante ao virossoma, e, kit para induzir uma resposta imune contra uma proteína gp41 de um vírus da imunodeficiência humana
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
CU23586A1 (es) Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
BRPI0607097B8 (pt) uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
BRPI0906710B8 (pt) peptídeo derivado de pres modificado hidrofóbico de vírus da hepatite b (hbv) , peptídeo e composição farmacêutica
EA201100072A1 (ru) Новые композиции и способы
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112022004058A2 (pt) Conjugados, populações de conjugados, composição farmacêutica, métodos para o tratamento de um sujeito com uma infecção viral, o tratamento profilático de uma infecção viral, para prevenir uma infecção secundária e para tratar ou prevenir uma infecção viral
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
BRPI0407840B8 (pt) vírus do sarampo recombinante, composição farmacêutica, uso de uma composição farmacêutica, célula bacteriana, método para produzir um vírus recombinante e uso
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112021023957A2 (pt) Peptídeos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/867 , C07K 14/18

Ipc: C12N 15/867 (2006.01), C07K 14/18 (2006.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF